Cardiovascular Manifestations of HIV Infection

Rerkpattanapipat P. , Wongpraparut N. , Jacobs L.E. , Kotler M.N. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 2000; 160: 602–8

Lipshultz S.E. , Easley D.A. , Orav E.J. Cardiac dysfunction and mortality in HIV-infected children. The Prospective P2C2 HIV Multicenter Study. Circulation 2000; 102: 1542–8

Temesgen Z. Overview of HIV infection. Ann Allergy Asthma Immunol 1999; 83: 1–5

Barbaro G. , Di Lorenzo G. , Grisorio B. , Barbarini G. for the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS investigators. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV positive patients. N Engl J Med 1998; 339: 1093–9

Lipshultz S.E. Dilated cardiomyopathy in HIV-infected patients [Editorial]. N Engl J Med 1998; 339: 1153–5

Barbaro G. , Di Lorenzo G. , Soldini M. The intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Circulation 1999; 100: 633–9

Barbaro G. , Di Lorenzo G. , Grisorio B. , Barbarini G. and Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS investigators. Cardiac involvement in the acquired immunodeficiency syndrome. A multicenter clinical-pathological study. AIDS Res Hum Retroviruses 1998; 14: 1071–7

Barbaro G. , Di Lorenzo G. , Soldini M. Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of TNF-α and iNOS. AIDS 2000; 14: 827–38

Lipshultz S.E. , Orav E.J. , Sanders S.P. , Colan S.D. Immunoglobulins and left ventricular structure and function in paediatrics HIV infection. Circulation 1995; 92: 2220–5

Currie P.F. , Goldman J.H. , Caforio A.L. Cardiac autoimmunity in HIV related heart muscle disease. Heart 1998; 79: 599–604

Gullestad L. , Aass H. , Fjeld J.G. Immunomodulatingtherapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220–5

Gherardi R. , Belec L. , Mhiri C. The spectrum of vasculitis in human immunodeficiency virus-infected patients. A clinicopathologic evaluation. Arthritis Rheum 1993; 36: 1164–74

Chi D. , Henry J. , Kelly J. , Thorpe R. , Smith J.K. , Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000; 7: 223–42

Sullivan A.K. , Nelson M.R. , Moyle G.J. , Newell A.M. , Feher M.D. , Gazzard B.G. Coronary artery disease occurring with protease inhibitor therapy. Int J STD AIDS 1998; 9: 711–12

Henry K. , Melrow H. , Huebsch J. Severe coronary heart disease with protease inhibitors [Letter]. Lancet 1998; 351: 1328

Behrens G. , Schmidt H. , Meyer D. , Stoll M. , Schmidt R.E. Vascular complications associated with use of HIV protease inhibitors [Letter]. Lancet 1998; 351: 1958

Jutte A. , Schwenk A. , Franzen C. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? [Letter] AIDS 1999; 13: 1796–7

Flynn T.E. , Bricker L.A. Myocardial infarction in HIV-infected men receiving protease inhibitors [Letters]. Ann Intern Med 1999; 131: 548

Beherns G.M. , Stoll M. , Schmidt R.E. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 2000; 23: 57–76

Dube M.P. , Sprecher D. , Henry W.K. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31: 1216–24

Currier J.S. How to manage metabolic complications of HIV therapy: what to do while we wait for answers. AIDS Read 2000; 10: 162–9

Penzak S.R. , Chuck S.K. , Stajich G.V. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000; 20: 1066–71

Aoun S. , Ramos E. Hypertension in the HIV-infected patient. Curr Hypertens Rep 2000; 2: 478–81

Pellicelli A. , Barbaro G. , Palmieri F. Primary pulmonary hypertension in HIV disease: a systematic review. Angiology 2001; 52: 31–41

Pellicelli A.M. , Palmieri F. , D'Ambrosio C. Role of human immunodeficiency virus in primary pulmonary hypertension: case reports. Angiology 1998; 49: 1005–11

Mesa R.A. , Edell E.S. , Dunn W.F. , Edwards W.D. Human immunodeficiency virus infection and pulmonary hypertension. Mayo Clin Proc 1998; 73: 37–44

Heidenreich P.A. , Eisenberg M.J. , Kee L.L. Pericardial effusion in AIDS. Incidence and survival. Circulation 1995; 92: 3229–34

Herskowitz A. , Willoughby S.B. , Baughman K.L. , Schulman S.P. , Bartlett J.D. Cardiomyopathy associated with anti-retroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 1992; 116: 311–13

Domanski M.J. , Sloas M.M. , Follman D.A. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. Paediatrics 1995; 127: 137–46

Lewis W. , Grupp I.L. , Grupp G. Cardiac dysfunction in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000; 80: 187–97

Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Prog Cardiovasc Dis 2000; 43: 151–70

Lipshultz S.E. , Orav E.J. , Sanders S.P. , Hale H.R. , McIntosh K. , Colan S.D. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med 1992; 327: 1260–5

Lipshultz S.E. , Easley K.A. , Orav E.J. Absence of cardiac toxicity of zidovudine in infants. N Engl J Med 2000; 343: 759–66

Sonnenblick E.H. , Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest 1991; 99: 557–61

Deyton L. , Walker R. , Kovacs J. Reversible cardiac dysfunction associated with interferon alpha therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med 1989; 321: 1246–9

Bristow M.R. , Mason J.W. , Billingham M.E. , Daniels J.R. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 1978; 88: 168–75

Brown D.L. , Sather S. , Cheitlin M.D. Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient. Am Heart J 1993; 125: 1439–41

Raine A.E. Hypertension, blood viscosity and cardiovascular morbidity in renal failure: implication of erythropoietin therapy. Lancet 1998; 1: 97–100

Arsura E.L. , Ismail Y. , Freeman S. , Karunakav A.R. Amphotericin B-induced dilated cardiomyopathy. Am J Med 1994; 97: 560–2

Cohen A.J. , Weiser B. , Afzal Q. , Fuhrer J. Ventricular tachycardia in two patients with AIDS receivingganciclovir (DHPG). AIDS 1990; 4: 807–9

Lopez J.A. , Harold J.G. , Rosenthal M.C. , Oseran D.S. , Schapira J.N. , Peter T. QT prolongation and torsade de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 1987; 59: 376–7

Giancaspro G. , Barbaro G. Disturbi del ritmo nella malattia da HIV/AIDS. In: Barbaro G. , Pellicelli A.M. , Barbarini G. , eds. Cardiologia nell'AIDS. Milan: Excerpta Medica, 200: 267–75

Michalets E.L. , Williams C.R. Drug interactions with cisapride: clinical manifestations. Clin Pharmacokinet 2000; 39: 49–75

Hoffman M. , Lipshultz S.E. , Miller T.L. Malnutrition and cardiac abnormalities in the HIV-infected patients. In: Miller T.L. , Gorbach S. , eds. Nutritional Aspects of HIV Infection. London: Arnold, 1999: 33–9

Beck M.A. , Kolbeck P.C. , Shi Q. , Rohr L.H. , Morris V.C. , Levander O.A. Increased virulence of a human enterovirus (coxackievirus B3) in selenium-deficient mice. J Infect Dis 1994; 170: 351–7

Yunis N.A. , Stone V.E. Cardiac manifestations of HIV/AIDS: a review of disease spectrum and clinical management. J AIDS Hum Retrovirol 1998; 18: 145–54